Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Swiss Cancer Institute
Swiss Cancer Institute
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-sen University
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Baptist Health South Florida
Northwestern University
Thomas Jefferson University
M.D. Anderson Cancer Center
Intergroupe Francophone de Cancerologie Thoracique
Hackensack Meridian Health
Guangdong Association of Clinical Trials
Massachusetts General Hospital
Intergroupe Francophone de Cancerologie Thoracique
Institut du Cancer de Montpellier - Val d'Aurelle
University Hospital, Lille
Jonsson Comprehensive Cancer Center
Mayo Clinic
Guangzhou Medical University
Montefiore Medical Center
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
Dana-Farber Cancer Institute
Beijing Cancer Prevention & Treatment Society
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Big Ten Cancer Research Consortium
Sun Yat-sen University
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
University of Utah
Mayo Clinic
NRG Oncology
Intergroupe Francophone de Cancerologie Thoracique
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
University of Kentucky
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Latin American Cooperative Oncology Group
Masonic Cancer Center, University of Minnesota
University of Alabama at Birmingham
University Hospital, Essen
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University